Asthma population (n = 262) | |
---|---|
Age (years) | 54.03 (14.9) |
Sex (% male) | 37.4 |
GINA Treatment Stepa | 5 (4–5) Step 4: 124 Step 5: 96 |
Sputum Eosinophil (%)a | 3.5 (0.5-18.75) |
% on ICS/LABA combination therapy (number) | 94.5 (n = 247) |
% on Montelukast (number) | 27.1 (n = 71) |
% on oral theophylline (number) | 32.4 (n = 85) |
% on Inhaled Tiotrpoium Bromide (number) | 26.0 (n = 68) |
% on maintenance oral prednisolone (number) | 53.8 (n = 156) |
Dose (mg/24 h) in those on Prednisolone | 10 (5.0–12.5)a |
Self-reported gastrointestinal reflux (%) | 49.0 |
Nasal polyps (%) (number) | 26.3 (n = 69) |
Perennial/seasonal rhinitis % (number) | 58.3 (n = 153) |
Smoking history (pack years) | 7.2 (2.6–20) |
Exacerbations in past year | 3 (1.0–6.0)a |
ITU admissions in past year | 0.0 (0.0–0.0)a |
Total ITU admissions | 0.0 (0.0–1.0)a |
Hospital admissions in past year | 0.0 (0.0–1.0)a |
Unscheduled GP/A&E visits | 3.0 (0.0–7.0)a |
Smoking history (pack years) | 7.2 (2.6–20)a |
Proportion of current: ex smokers | Current smokers: n = 19 Ex-smokers: n = 76 |
% Smoking >10 pack years (number) | 16 .0 (n = 42) |
Post Bronchodilator FEV1 (% Predicted) | 73.33 (35.7) |
Post Bronchodilator FVC (% Predicted) | 96.6 (154..4) |
Post Bronchodilator FEV1/FVC (%) | 66.82 (14.6) |
GLI FEV1 Z score | −1.67 (2.68) |
Bronchodilator reversibility (%) | 14.13 (19.01) |
ACQ-6 scorea | 2.50 (1.5–3.5)a |
AQLQ scorea | 3.83 (3.0–5.1)a |
LCQ Total scorea | 15.48 (11.6–19.2)a |
LCQ Total score (females)a | 14.9 (10.8–18.7) [n = 164] |
LCQ Total Score (males)a | 17.1 (12.8–19.8) [n = 98] |
LCQ Total score (smoker <10 pack/years) | 16.22 (11.3–19.0) |
LCQ Total score (smoker ≥10 pack/years) | 15.4 (12.7–19.8) |
LCQ Physicala | 4.75 (3.6–6.0)a |
LCQ Psychologicala | 5.57 (4.0–6.7)a |
LCQ Sociala | 5.38 (3.8–6.8)a |